MOCS1 (molybdenum cofactor synthesis 1) encodes the first two enzymes (MOCS1A and MOCS1B) required for molybdenum cofactor (MoCo) biosynthesis through a unique bicistronic mechanism 1. The gene product catalyzes GTP 3',8'-cyclase activity to synthesize cyclic pyranopterin monophosphate, the initial step in MoCo synthesis 2. MoCo is essential for the activity of four human molybdoenzymes: sulfite oxidase, xanthine dehydrogenase, aldehyde oxidase, and mitochondrial amidoxime reducing component 3. Mutations in MOCS1 cause molybdenum cofactor deficiency type A, an autosomal recessive disorder characterized by neonatal-onset myoclonic epileptic encephalopathy 4. The severe neurological phenotype primarily results from sulfite oxidase deficiency, leading to toxic sulfite accumulation in the brain 2. MOCS1 mutations account for the majority of MoCo deficiency cases, with multiple recurrent mutations identified globally 1. At the cellular level, MOCS1 deficiency causes mitochondrial bioenergetic dysfunction, reduced ATP production, increased superoxide production, and endoplasmic reticulum stress, triggering apoptosis 5. However, type A deficiency has therapeutic potential: cyclic pyranopterin monophosphate substitution therapy effectively reduces sulfite toxicity and restores biochemical homeostasis, with clinical outcomes dependent on timing of intervention 4. Recent studies demonstrate metformin restores mitochondrial function through biogenesis modulation in MOCS1-deficient cells 6.